Condition
IgAVN
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 3 (2)
Trial Status
Not Yet Recruiting2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07024563Phase 3Recruiting
Study of Ravulizumab in Pediatric Participants With Primary IgAN
NCT07354503Not Yet RecruitingPrimary
Telitacicept in the Treatment of Pediatric IgA Vasculitis-Associated Nephritis
NCT07052981Phase 3Not Yet Recruiting
Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis
Showing all 3 trials